The European Health Management Association (EHMA), together with partners in the PREVENT Project, is conducting an exploratory survey to better understand how primary prevention interventions targeting childhood and adolescent overweight and obesity can be scaled across Europe.
The PREVENT Project is a Horizon Europe initiative under the EU Mission on Cancer, bringing together partners from seven European countries to address one of the major public health challenges facing Europe today. Research indicates that childhood obesity significantly increases the risk of cancer in adulthood, highlighting the importance of effective prevention strategies early in life.
As part of this work, the project consortium is gathering insights from experts across Europe to assess the relevance, feasibility, and readiness for implementing prevention interventions in different national contexts.
The survey explores key factors that influence the successful scale-up of childhood obesity prevention strategies, including policy support, organisational capacity, financial sustainability, cultural factors, and multi-stakeholder collaboration.
The questionnaire:
Takes approximately 5–10 minutes to complete
Is available in all EU official languages
Includes both structured and open-ended questions
Is anonymous and voluntary, with responses analysed in aggregated form
The results will contribute to the development of a report later this year and help inform practical guidance for scaling up prevention initiatives across Europe.
The survey is intended for professionals with knowledge of health systems, public health policy, education systems, or childhood obesity prevention initiatives in their country or region. Contributions from paediatricians, public health professionals, policymakers, researchers, and organisational leaders are particularly valuable. Colleagues are also welcome to share the survey with other experts who may wish to contribute.
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.
